| |
|
|
|
|
The following is an excerpt from a 10-Q SEC Filing, filed by ABBOTT LABORATORIES on 8/14/2001. |
|
|
|
|
|
ABBOTT LABORATORIES - 10-Q - 20010814 - CASH_FLOW
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in thousands)
|
|
Six Months Ended
June 30
|
|
|
|
2001
|
|
2000
|
|
|
Cash Flow From (Used in) Operating Activities:
|
|
|
|
|
|
|
|
|
|
Net earnings
|
|
$
|
305,435
|
|
$
|
1,378,159
|
|
|
|
Adjustments to reconcile net earnings to net cash from operating activities -
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
541,253
|
|
|
435,773
|
|
|
|
Acquired in-process research and development
|
|
|
1,187,000
|
|
|
—
|
|
|
|
Trade receivables
|
|
|
40,097
|
|
|
(49,696
|
)
|
|
|
Inventories
|
|
|
(189,325
|
)
|
|
(252,334
|
)
|
|
|
Gain on sale of business
|
|
|
—
|
|
|
(138,507
|
)
|
|
|
Other, net
|
|
|
(389,380
|
)
|
|
274,159
|
|
|
|
|
|
|
|
|
|
|
|
Net Cash From Operating Activities
|
|
|
1,495,080
|
|
|
1,647,554
|
|
|
|
|
|
|
|
|
|
Cash Flow From (Used in) Investing Activities:
|
|
|
|
|
|
|
|
|
|
Proceeds from sale of business
|
|
|
—
|
|
|
116,000
|
|
|
|
Acquisition of the pharmaceutical business of BASF
|
|
|
(6,826,102
|
)
|
|
—
|
|
|
|
Acquisitions of property, equipment and businesses
|
|
|
(391,390
|
)
|
|
(530,845
|
)
|
|
|
Investment securities transactions
|
|
|
2,214
|
|
|
32,450
|
|
|
|
Other
|
|
|
16,914
|
|
|
36,034
|
|
|
|
|
|
|
|
|
|
|
|
Net Cash Used in Investing Activities
|
|
|
(7,198,364
|
)
|
|
(346,361
|
)
|
|
|
|
|
|
|
|
|
Cash Flow From (Used in) Financing Activities:
|
|
|
|
|
|
|
|
|
|
Proceeds from (repayments of) commercial paper, net
|
|
|
5,995,000
|
|
|
(548,000
|
)
|
|
|
Other borrowing transactions, net
|
|
|
58,566
|
|
|
(590
|
)
|
|
|
Common share transactions
|
|
|
90,080
|
|
|
49,986
|
|
|
|
Dividends paid
|
|
|
(619,010
|
)
|
|
(557,462
|
)
|
|
|
|
|
|
|
|
|
|
|
Net Cash From (Used in) Financing Activities
|
|
|
5,524,636
|
|
|
(1,056,066
|
)
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
(70,823
|
)
|
|
(13,075
|
)
|
|
|
|
|
|
|
|
|
Net (Decrease) Increase in Cash and Cash Equivalents
|
|
|
(249,471
|
)
|
|
232,052
|
|
|
Cash and Cash Equivalents, Beginning of Year
|
|
|
914,218
|
|
|
608,097
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents, End of Period
|
|
$
|
664,747
|
|
$
|
840,149
|
|
|
|
|
|
|
|
|
|
|
|
|
Next Section
Previous Section